Seeking Alpha

Prosensa begins dosing first patient in Phase I/II trials of PR0053

  • Prosensa Holding (RNA +1.3%) says it's begun dosing the first patient in its Phase I/II clinical trial of PRO053, a treatment for Duchenne muscular dystrophy.
  • The trial is designed to assess the safety, efficacy, tolerability and pharmacokinetics of multiple doses of PRO053 in a subset of patients with the disease.
  • The company says PRO053 induces exon 53 skipping and may be applicable to about 8% of all DMD patients.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)